Vedere Bio II, Inc.® is a company developing next generation ocular gene therapies designed for vision restoration and preservation for patients with vision loss due to photoreceptor death.

Biotechnology

Vedere Bio

Vedere Bio's headquarters in Cambridge, MA, United States

Ellen Zyrkowski

Xiaozhi Ren (任小峙) Ph.D.

Karen Guerin

Soraya Bekkali, MD

Daniel Zimmer

John Flannery

Ehud Isacoff

The Leadership Team at Vedere Bio is responsible for setting the strategic direction of the company and overseeing the development of innovative ocular gene therapies. This team, comprised of co-founders and experts in science, regulatory affairs, and operations, collaborates to drive research initiatives, regulatory compliance, and operational efficiency, ensuring the successful translation of cutting-edge treatments into clinical practice for patients with vision loss.

Leadership Team

The Research and Development team at Vedere Bio focuses on pioneering ocular gene therapies to restore and preserve vision in patients suffering from vision loss due to photoreceptor death. This team drives innovative discovery research, develops cell lines and processes, and leads critical programs to advance therapeutic solutions from concept to clinical application.

Vedere Bio

Org chart

Board & advisors

Teams

Leadership Team

Research and Development

Offices

Vedere Bio

Org chart

Board & advisors

Teams

Leadership Team

Research and Development

Offices

Related companies